Project Grant R01HL184432
Award Date 8/10/26
Completion Date 7/31/28
Dollars Obligated $3.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $2,401,048 for Project Grant R01HL184086 on September 1, 2026 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds GO MOMS PREDICT, a prospective study that develops and tests pregnancy-based cardiovascular disease risk assessment models to predict cardiovascular outcomes five years after delivery. The study leverages an existing...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital (MGH) a $709,917 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective September 17, 2025, through July 31, 2030, to conduct genomic research on peripartum cardiomyopathy (PPCM). The research will investigate the genetic factors underlying PPCM, a leading cause of maternal mortality characterized by sudden heart muscle weakening during late...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $614,843 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research examining the relationship between indexed exercise blood pressure and adverse vascular and ventricular remodeling as risk factors for heart failure with preserved ejection fraction (HFPEF). The research investigates whether the ratio of peak...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded the Massachusetts General Hospital's Research Management Division $842,536 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanisms linking gestational diabetes mellitus (GDM) to increased coronary artery disease risk in women. The research integrates longitudinal electronic health records data spanning approximately 30 years postpartum for more than 208,000 women with GDM...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $391,700 under the Cardiovascular Diseases Research program (CFDA 93.837) on February 15, 2026. The award funds mixed-methods health services research to optimize the regionalization of care for acute type A aortic dissection (ATAAD) and increase appropriate interfacility transfer of ATAAD patients from low-volume to high-volume aortic centers. The research...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $121,345 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026. The award funds development of positron emission tomography (PET) imaging of oxidized collagen as a biomarker for myocardial fibrosis in heart failure with preserved ejection fraction (HFpEF). The project focuses on targeted PET imaging probes that bind...
- The National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $867,656 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, to develop and apply comparative effectiveness evidence methods for evaluating medical therapies in heart failure with mildly reduced ejection fraction (HFMREF). The award funds completion of the largest echocardiography registry in the world and application of regression discontinuity...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $197,634 in project grant funding on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This K23 mentored research award funds investigation of inhaled nitric oxide (INO) responder and non-responder phenotypes in persistent pulmonary hypertension of the newborn (PPHN) using electrical impedance tomography (EIT)...
- The National Heart, Lung, and Blood Institute awarded Massachusetts General Hospital $747,256 under Cardiovascular Diseases Research (CFDA 93.837) on August 17, 2026, to investigate the role of METTL3 (a methyltransferase enzyme) in heart failure with preserved ejection fraction (HFpEF). The project addresses an unmet clinical need: no pharmacological therapy has been proven to improve survival in HFpEF, the most prevalent form of heart failure particularly among patients with metabolic...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital a $247,500 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 1, 2025 through August 31, 2027. The award supports research to develop a non-invasive biomarker-based classifier model for early detection of pulmonary vascular dysfunction (PVD) in acute respiratory distress syndrome (ARDS) patients. ARDS patients with PVD...